Mark Kaminski

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

Zheng Zhou, Laurie H. Sehn, Alfred Rademaker et al. · Blood · 2013 · 934 citations · Full text

¹³¹I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma

Mark Kaminski, Melissa Tuck, Judith Estes et al. · New England Journal of Medicine · 2005 · 714 citations · Full text

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 707 citations · Full text

Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas

Mark Kaminski, Andrew D. Zelenetz, Oliver W. Press et al. · Journal of Clinical Oncology · 2001 · 584 citations

Radioimmunotherapy of B-Cell Lymphoma with [¹³¹I]Anti-B1 (Anti-CD20) Antibody

Mark Kaminski, Kenneth Zasadny, Isaac R. Francis et al. · New England Journal of Medicine · 1993 · 548 citations · Full text